A Realistic View Of Belviq In The Short Term [View article]
Thank you for this article. It is refreshing to finally hear analysis based on a severely neglected piece of the ARNA picture- the prescribing behavior of physicians in the setting of new pharmacologic therapies in light of readily available non-pharmacologic interventions. I feel ARNA is very promising in the long term but it will get off the starting block at a jog long before it has a chance to break into a run.
Both products are a bust. There is no cost or outcome advantage to Rayos or Duexis compared to existing (and significantly cheaper) therapies which are for all-intents-and-purposes identical to these 'innovations'.
This Week's Biotech Summary (December 16-21, 2012) [View article]
A Reasoned Case For Celsion's ThermoDox [View article]
A Realistic View Of Belviq In The Short Term [View article]
4 Reasons To Buy Horizon Pharma [View article]